LIXTE Biotechnology Holdings to Present at Two Investor Conferences
LIXTE Biotechnology Holdings (Nasdaq: LIXT) announced its participation in two upcoming investor conferences. The company will present at the Investor Summit Summer 2024 Virtual Conference on August 20, 2024, at 2 p.m. EDT, and the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.
CEO Bas van der Baan will provide an overview of LIXTE's clinical trials with LB-100, their proprietary compound designed to enhance chemotherapy and immunotherapy treatments for cancer. The company is currently conducting proof-of-concept clinical trials for colorectal, ovarian, and sarcoma cancers, including trials funded by GSK and Roche.
Investors can access the presentations through LIXTE's investor relations website and the H.C. Wainwright conference registration page.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda presenterà al Investor Summit Summer 2024 Virtual Conference il 20 agosto 2024, alle 14:00 EDT, e al H.C. Wainwright 26th Annual Global Investment Conference dal 9 all'11 settembre 2024.
Il CEO Bas van der Baan fornirà una panoramica degli studi clinici di LIXTE con LB-100, il loro composto proprietario progettato per migliorare i trattamenti di chemioterapia e immunoterapia per il cancro. Attualmente, l'azienda sta conducendo studi clinici di proof-of-concept per i cancro colorettale, ovarico e sarcoma, inclusi studi finanziati da GSK e Roche.
Gli investitori possono accedere alle presentazioni tramite il sito web delle relazioni con gli investitori di LIXTE e la pagina di registrazione della conferenza H.C. Wainwright.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) anunció su participación en dos próximas conferencias para inversionistas. La compañía presentará en la Investor Summit Summer 2024 Virtual Conference el 20 de agosto de 2024, a las 2 p.m. EDT, y en la H.C. Wainwright 26th Annual Global Investment Conference del 9 al 11 de septiembre de 2024.
El CEO Bas van der Baan ofrecerá una visión general de los ensayos clínicos de LIXTE con LB-100, su compuesto propio diseñado para mejorar los tratamientos de quimioterapia e inmunoterapia para el cáncer. La empresa está realizando actualmente ensayos clínicos de prueba de concepto para el cáncer colorrectal, ovárico y sarcoma, incluidos ensayos financiados por GSK y Roche.
Los inversores pueden acceder a las presentaciones a través del sitio web de relaciones con inversores de LIXTE y la página de registro de la conferencia H.C. Wainwright.
LIXTE Biotechnology Holdings (Nasdaq: LIXT)은 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 2024년 8월 20일 오후 2시에 개최되는 Investor Summit Summer 2024 Virtual Conference와 2024년 9월 9일부터 11일 사이에 열리는 H.C. Wainwright 26th Annual Global Investment Conference에서 발표할 예정입니다.
CEO Bas van der Baan은 LB-100과 관련된 LIXTE의 임상 시험에 대한 개요를 제공할 것입니다. 이들은 암 치료의 화학 요법과 면역 요법을 강화하기 위해 설계된 자사의 독점 화합물입니다. 현재 회사는 대장암, 난소암 및 육종암에 대한 개념 검증 임상 시험을 진행 중이며, 이에는 GSK 및 Roche의 자금을 지원받은 시험도 포함됩니다.
투자자는 LIXTE의 투자자 관계 웹사이트 및 H.C. Wainwright 회의 등록 페이지를 통해 발표에 접근할 수 있습니다.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) a annoncé sa participation à deux prochaines conférences pour investisseurs. La société présentera lors de la Investor Summit Summer 2024 Virtual Conference le 20 août 2024 à 14h00 EDT, et lors de la H.C. Wainwright 26th Annual Global Investment Conference du 9 au 11 septembre 2024.
Le PDG Bas van der Baan donnera un aperçu des essais cliniques de LIXTE avec LB-100, leur composé exclusif conçu pour améliorer les traitements de chimiothérapie et d'immunothérapie pour le cancer. L'entreprise mène actuellement des études cliniques de preuve de concept pour les cancers colorectaux, ovariens et sarcomes, y compris des essais financés par GSK et Roche.
Les investisseurs peuvent accéder aux présentations via le site web des relations investisseurs de LIXTE et la page d'inscription de la conférence H.C. Wainwright.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 20. August 2024 um 14 Uhr EDT auf der Investor Summit Summer 2024 Virtual Conference präsentieren und von 9. bis 11. September 2024 auf der H.C. Wainwright 26th Annual Global Investment Conference.
CEO Bas van der Baan wird einen Überblick über die klinischen Studien von LIXTE mit LB-100 geben, ihrem proprietären Wirkstoff, der darauf abzielt, Chemotherapie und Immuntherapie bei Krebs zu verbessern. Das Unternehmen führt derzeit proof-of-concept klinische Studien für kolorektale, ovarielle und Sarkom-Krebserkrankungen durch, einschließlich Studien, die von GSK und Roche finanziert werden.
Investoren können auf die Präsentationen über die Investor-Relations-Website von LIXTE und die Registrierungsseite der H.C. Wainwright-Konferenz zugreifen.
- None.
- None.
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference;
and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference-
PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences:
- The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/11 a.m. PDT. To access the presentation, visit LIXTE’s investor relations website at https://ir.lixte.com/news-events/ir-calendar.
- The H.C. Wainwright 26th Annual Global Investor Conference, on demand starting at 7 a.m. EDT/4 a.m. PDT, September 9-11, 2024. To access the virtual presentation, register for the conference at www.hcwevents.com/annualconference.
Bas van der Baan, CEO of LIXTE, will present an overview of the Company’s clinical trials with LB-100, its proprietary compound focused on enhancing chemotherapy and immunotherapy treatments as cancer therapies. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers, including trials funded by GSK and Roche.
About LIXTE Biotechnology Holdings
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers. Additional information about LIXTE can be found at www.lixte.com.
For more information about LIXTE, Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations
pwinvestor@pondel.com
Roger Pondel: (310) 279-5965
Laurie Berman: (310) 279-5962
# # #
FAQ
When is LIXTE Biotechnology Holdings (LIXT) presenting at the Investor Summit Summer 2024 Virtual Conference?
What is the date range for LIXTE Biotechnology's (LIXT) presentation at the H.C. Wainwright 26th Annual Global Investment Conference?
What types of cancer is LIXTE Biotechnology (LIXT) currently conducting clinical trials for with LB-100?